Browsing by Author "Makinson R.A."

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • No Thumbnail Available
    ItemMetadata only
    Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
    (2022-04-08) Ogbe A.; Pace M.; Bittaye M.; Tipoe T.; Adele S.; Alagaratnam J.; Aley P.K.; Ansari M.A.; Bara A.; Broadhead S.; Brown A.; Brown H.; Cappuccini F.; Cinardo P.; Dejnirattisai W.; Ewer K.J.; Fok H.; Folegatti P.M.; Fowler J.; Godfrey L.; Goodman A.L.; Jackson B.; Jenkin D.; Jones M.; Longet S.; Makinson R.A.; Marchevsky N.G.; Mathew M.; Mazzella A.; Mujadidi Y.F.; Parolini L.; Petersen C.; Plested E.; Pollock K.M.; Rajeswaran T.; Ramasamy M.N.; Rhead S.; Robinson H.; Robinson N.; Sanders H.; Serrano S.; Tipton T.; Waters A.; Zacharopoulou P.; Barnes E.; Dunachie S.; Goulder P.; Klenerman P.; Screaton G.R.; Winston A.; Hill A.V.S.; Gilbert S.C.; Carroll M.; Pollard A.J.; Fidler S.; Fox J.; Lambe T.; Frater J.; Mahidol University
    Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.